Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis

BACKGROUND: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist that recently demonstrated efficacy in delaying chronic kidney disease progression and reducing cardiovascular events in patients with chronic kidney disease and type 2 diabetes in FIDELIO-DKD, where 5734 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Berg, Paul, Ruppert, Martijn, Mesic, Emir, Snelder, Nelleke, Seelmann, Andreas, Heinig, Roland, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891099/
https://www.ncbi.nlm.nih.gov/pubmed/34773606
http://dx.doi.org/10.1007/s40262-021-01082-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891099/
https://www.ncbi.nlm.nih.gov/pubmed/34773606
http://dx.doi.org/10.1007/s40262-021-01082-2

Ejemplares similares